AR072359A1 - Encapsulacion de agentes biologicamente activos - Google Patents

Encapsulacion de agentes biologicamente activos

Info

Publication number
AR072359A1
AR072359A1 ARP090101617A ARP090101617A AR072359A1 AR 072359 A1 AR072359 A1 AR 072359A1 AR P090101617 A ARP090101617 A AR P090101617A AR P090101617 A ARP090101617 A AR P090101617A AR 072359 A1 AR072359 A1 AR 072359A1
Authority
AR
Argentina
Prior art keywords
biologically active
active agent
encapsulation
aqueous
active agents
Prior art date
Application number
ARP090101617A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40944671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072359(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR072359A1 publication Critical patent/AR072359A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Composiciones que comprenden vehículos en forma de partículas que pueden obtenerse por dichos procedimientos y usos de dichas composiciones en un tratamiento. Reivindicacion 1: Un procedimiento para producir un vehículo en forma de partículas que comprende las etapas de: a) disolver polibutilcianoacrilato (PBCA) en un disolvente orgánico para formar una solucion polimérica; b) anadir una solucion acuosa que contiene un agente biologicamente activo a la solucion polimérica para formar una emulsion primaria de gotas de fase acuosa en una fase orgánica continua; c) mezclar la emulsion primaria con un medio acuoso para formar una emulsion secundaria; y d) permitir que la fase orgánica se evapore y por lo tanto obtener vehículos en forma de partículas que comprende una luz hueca que contiene el agente biologicamente activo en una fase acuosa. Reivindicacion 6: El procedimiento de una cualquiera de las reivindicaciones 1 a 4, en el que el vehículo en forma de partículas es una nanopartícula. Reivindicacion 7: El procedimiento de una cualquiera de las reivindicaciones 1 a 6, en el que el agente biologicamente activo es una proteína o péptido.
ARP090101617A 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos AR072359A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20

Publications (1)

Publication Number Publication Date
AR072359A1 true AR072359A1 (es) 2010-08-25

Family

ID=40944671

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP090101618A AR071634A1 (es) 2008-05-06 2009-05-05 Nanoparticulas para encapsulacion de agentes biologicamente activos
ARP090101616A AR071633A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
ARP090101619A AR072668A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
ARP090101617A AR072359A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ARP090101618A AR071634A1 (es) 2008-05-06 2009-05-05 Nanoparticulas para encapsulacion de agentes biologicamente activos
ARP090101616A AR071633A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos
ARP090101619A AR072668A1 (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos

Country Status (11)

Country Link
US (1) US20110064821A1 (es)
EP (2) EP2271323A2 (es)
JP (1) JP2011522792A (es)
KR (3) KR20110010758A (es)
AR (4) AR071634A1 (es)
CA (1) CA2721241A1 (es)
CL (4) CL2009001076A1 (es)
PE (4) PE20091882A1 (es)
TW (4) TW201006495A (es)
UY (4) UY31808A (es)
WO (1) WO2009135853A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721307A1 (en) * 2008-05-06 2009-11-12 Glaxo Group Limited Encapsulation of biologically active agents
US9504759B2 (en) 2011-08-11 2016-11-29 Bar-Ilan University Surface modified proteinaceous spherical particles and uses thereof
US10112988B2 (en) 2012-01-09 2018-10-30 Icb International, Inc. Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
US10112987B2 (en) * 2012-01-09 2018-10-30 Icb International, Inc. Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
JP6612333B2 (ja) * 2014-05-30 2019-11-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 高薬物負荷ポリ（アルキル２−シアノアクリレート）ナノカプセル
CA2946810A1 (en) * 2014-05-30 2015-12-03 AbbVie Deutschland GmbH & Co. KG Nanoencapsulation of antigen-binding molecules
EP3154524B1 (en) * 2014-06-12 2021-12-15 Adare Pharmaceuticals USA, Inc. Extended-release drug delivery compositions
EP3160449B1 (en) 2014-06-24 2023-12-13 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
WO2019055539A1 (en) 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
US20220031630A1 (en) * 2018-09-13 2022-02-03 The Brigham And Women's Hospital, Inc. Nanoparticle formulations and methods of their use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833666A (en) 1986-12-24 1989-05-23 U.S. Philips Corporation Disc-record player suitable for scanning disc of different types
FR2649321A1 (fr) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med Compositions a base de derives nucleotidiques, leurs procedes de preparation, et leurs utilisations notamment en tant que compositions pharmaceutiques
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
EP0683667A1 (en) * 1993-02-15 1995-11-29 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
CA2171303C (en) * 1993-09-09 2006-06-06 Werner Weitschies Active principles and gas containing microparticles
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
US7417130B2 (en) 2000-09-08 2008-08-26 University Of Zurich Collection of repeat proteins comprising repeat modules
WO2003005952A2 (en) * 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
JP4871126B2 (ja) 2003-07-04 2012-02-08 アフィボディ・アーベー Ｈｅｒ２に対する結合親和性を有するポリペプチド
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
WO2005056764A2 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
JP2008513363A (ja) 2004-09-14 2008-05-01 ナノデル テクノロジーズ ゲーエムベーハー ナノ粒子を含む送達媒体
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
PL2177536T3 (pl) 2006-03-30 2014-11-28 Glaxo Group Ltd Przeciwciała przeciwko peptydowi beta-amyloidu
EP1958957A1 (en) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
US8877186B2 (en) 2007-06-06 2014-11-04 Domantis Limited Polypeptides, antibody variable domains and antagonists
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery

Also Published As

Publication number Publication date
CL2009001076A1 (es) 2010-09-24
TW201012488A (en) 2010-04-01
US20110064821A1 (en) 2011-03-17
KR20110010758A (ko) 2011-02-07
AR071634A1 (es) 2010-06-30
AR071633A1 (es) 2010-06-30
CA2721241A1 (en) 2009-11-12
JP2011522792A (ja) 2011-08-04
PE20091829A1 (es) 2009-12-12
UY31809A (es) 2009-12-14
PE20091965A1 (es) 2010-01-09
EP2271323A2 (en) 2011-01-12
CL2009001077A1 (es) 2010-09-24
KR20110010760A (ko) 2011-02-07
PE20091882A1 (es) 2009-12-24
TW201012490A (en) 2010-04-01
UY31810A (es) 2009-12-14
WO2009135853A3 (en) 2011-05-12
AR072668A1 (es) 2010-09-15
CL2009001080A1 (es) 2010-09-24
CL2009001081A1 (es) 2010-09-24
TW201012489A (en) 2010-04-01
UY31808A (es) 2009-12-14
WO2009135853A2 (en) 2009-11-12
PE20091964A1 (es) 2010-01-09
TW201006495A (en) 2010-02-16
EP2441447A1 (en) 2012-04-18
KR20110015604A (ko) 2011-02-16
UY31807A (es) 2009-12-14

Similar Documents

Publication Publication Date Title
AR072359A1 (es) Encapsulacion de agentes biologicamente activos
PE20191714A1 (es) Nanoparticula polimerica de finasterida y minoxidil, proceso de preparacion, suspension acuosa conteniendo la misma, composicion farmaceutica, y su uso
AR092402A1 (es) Nanoparticula polimerica de finasterida, suspension acuosa conteniendo a la misma, composicion para tratamiento de alopecia, proceso de preparacion de dicha composicion, y su uso
CO2019005729A2 (es) Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos
PE20050926A1 (es) Composicion y forma de dosificacion que comprende una molecula anfifilica como un vehiculo de suspension
BRPI0518677A2 (pt) produto sàlido, processos para a produÇço de um produto sàlido e para a produÇço de uma nanodispersço estabilizada ou micela carregada, lÍquido translécido, mÉtodo de tratamento mÉdico, e, dispositivo para a produÇço de formulaÇÕes sàlidas de agentes biologicamente ativos lÍquidos
AR071239A1 (es) Microesferas que tienen una estructura de nucleo / recubrimiento que comprenden aripiprazol y uso
PE20080738A1 (es) Sistema de liberacion controlada y metodo para fabricarlo
CL2007003730A1 (es) Nanoemulsion que comprende a) componente acuoso y b) un vehiculo con i) 0,1-15% de un componente lipofilico, ii) un tensoactivo y iii) un alcohol c3-c5; composicion que la comprende opcionalmente con un agente activo; proceso de preparacion de la nanoemulsion y de la composicion; kit; y uso para diagnosticar enfermedades dermicas y proliferativas, y tratar enfermedades virales, dermicas y proliferativas.
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
BRPI0913326C1 (pt) formulação farmacêuticas tópicas contendo uma baixa concentração de peróxido de benzoíla em suspensão aquosa e um solvente orgânico miscível em água
CL2011002053A1 (es) Composicion farmaceutica de espuma en aerosol en emulsion de aceite en agua que comprende un agente farmaceuticamente activo, agua, aceite, disolvente organico, componente tensoactivo, y propulsor; procedimiento de preparacion; uso para tratar enfermedades, o afecciones de la piel.
PE20080765A1 (es) Formas de dosificacion farmaceutica
AR086115A1 (es) Formulaciones parenterales mejoradas de agentes farmaceuticos lipofilos y los metodos para la preparacion y el uso de las mismas
UY30587A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasa s janus
BR112015022985A2 (pt) Microesferas de buprenorfina de carga de fármaco alta e método para produção das mesmas
AR077155A1 (es) Nanodispersion, nanoparticulas y solucion
AR085181A1 (es) Composicion para el cuidado del cabello, metodo de elaboracion de la composicion, uso
CO6311052A2 (es) Una microemulsion que comprende un ingrediente activo, un solvente y un surfactante no ionico y proceso para su preparación
AR072921A1 (es) Mejoras relacionadas con composiciones que contienen agentes tensioactivos
AR087911A1 (es) Metodos en multiples etapas y composiciones para desensibilizar las caras de formaciones subterraneas
AR094291A1 (es) Formulacion inyectable de liberacion prolongada que comprende tolvaptan opticamente activo, y un procedimiento para producirla
ES2625873T3 (es) Método de preparación de micropartículas biodegradables que contienen fármacos
AR065564A1 (es) Composiciones farmaceuticas que comprenden un agente calciletico
AR064104A1 (es) Formas de dosificacion en microemulsion de valsartan, y metodos para elaborarlas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal